Description

Simple

Information currently not available.

Clinical

Information currently not available.

Overview

Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid[5] and it is the first monomeric ionic compound used as an X-ray contrast agent.[1] It was first synthesized by Wallingford in 1953[2] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978.[7] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[6]

Pharmacology

Indication

Acetrizoic acid indication was to be used as a contrast agent for X-ray. Some information indicates its nephrotropic property as one of the characteristics for the utilization of acetrizoic acid.[ Read more

Pharmacodynamic

Information currently not available.

Mechanism of action

Iodine, a big component in acetrizoic acid, is an element with a high atomic density. This property causes attenuation of X-rays within the diagnostic energy spectrum. Thus, acetrizoic acid is a water-soluble and reasonably safe iodinated contrast agent that can be intravenously administered for cli... Read more

Absorption

After intravenous administration, acetrizoic acid gets largely distributed in the extracellular fluid space.[4] Radiographic agents like acetrizoic agents present variations in the plasm... Read more

Protein binding

The radiographic agents such as acetrizoic acid are carried free in plasma in which less than 5% of the injected dose is protein bound.[9]

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

When water-soluble contrast agents, such as acetrizoic acid, are administered, it is reported a half-life of approximate 4 hours.[10]

Route of elimination

After intravenous administration, acetrizoic acid is mainly excreted unchanged by the kidney.[4] The elimination pathway is handled by a glomerular filtration and concentration by tubula... Read more

Toxicity

In preclinical studies performed in rodents, the LD50 after oral or intravenous administration was 2 g/kg and 8 g/kg respectively.[8]

Adverse Effects

Effect Regions Age Groups Incidences Evidence Type

Contraindications

Information currently not available.

Food Interactions

Information currently not available.